Onkologie. 2021:15(3):115-118 | DOI: 10.36290/xon.2021.021

Pelvic exenteration - gynecologic oncology surgery

Gabriel Jelenek, Richard Feranec, Josef Chovanec
Oddělení gynekologické onkologie, Klinika operační onkologie, Masarykův onkologický ústav a LF MU Brno

Pelvic exenteration is specific, complex and extensive operation which allows experienced surgical team with a good patient selection with a pelvic relaps to reach zero residuum resection. Radicality and specificity of such a procedure requires specific surgical skills, multidisciplinary team and centralisation of patients.

Keywords: pelvic exenteration, recurrence, salvage operation, en-block resection.

Published: May 6, 2021  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Jelenek G, Feranec R, Chovanec J. Pelvic exenteration - gynecologic oncology surgery. Onkologie. 2021;15(3):115-118. doi: 10.36290/xon.2021.021.
Download citation

References

  1. Mann WJ, Jr. Exenteration for gynecologic cancer. In: uptodate.com [online]. [cit. 09-2-2021]. Dostupné z: https://www.uptodate.com/contents/exenteration-for-gynecologic-can-cer?search=Exenteration%20for%20gynecologic%20cancer&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1
  2. Berek JS, Howe C, Lagasse LD, Hacker NF. Pelvic exenteration for recurrent gynecologic malignancy: survival and morbidity analysis of the 45-year experience at UCLA. Gynecol Oncol 2005; 99: 153. Go to original source... Go to PubMed...
  3. Cibula D. Pelvic Exenteration for Gynecologic cancers. In: Ramirez PT, et al. Principles of gynecologic oncology surgery, ISBN: 9780323428781. Elsevier 2018: Chapter 15, 193-206 Go to original source...
  4. Cibula D, Babjuk M, Mareš P, Svárovský J, Gürlich R, Ungár L, Pešková M, Freitag P, Dundr P, Martan A. Exenterace pánve. Klin Onkol 2005; 18(5): 184-187.
  5. Schneider A, Köhler C, Erdemoglu E. Current developments for pelvic exenteration in gynecologic oncology. Curr Opin Obstet Gynecol. 2009; 21(1): 4-9. doi:10.1097/GCO.0b013e32831c8436 Go to original source... Go to PubMed...
  6. Maggioni A, Roviglione G, Landoni F, Zanagnolo V, Peiretti M, Colombo N, Bocciolone L, Biffi R, Minig L, Morrow CP. Pelvic exenteration: Ten-year experience at the European Institute of Oncology in Milan. 2009; 114(1): 64-68. doi:10.1016/ j.ygyno.2009.03.029 Go to original source... Go to PubMed...
  7. Popovich MJ, Hricak H, Sugimura K, Stern JL. The role of MR imaging in determining surgical eligibility for pelvic exenteration. AJR Am J Roentgenol. 1993 Mar; 160(3): 525-31. doi: 10.2214/ajr.160.3.8430546. PMID: 8430546. Go to original source... Go to PubMed...
  8. Lai CH, Huang KG, See LC, Yen TC, Tsai CS, Chang TC, Chou HH, Ng KK, Hsueh S, Hong JH. Restaging of recurrent cervical carcinoma with dual-phase [18F]fluoro-2-deoxy-D-glucose positron emission tomography. Cancer. 2004 Feb 1; 100(3): 544-52. doi: 10.1002/cncr.11928. PMID: 14745871. Go to original source... Go to PubMed...
  9. Lucas R, Lopes Dias J, Cunha TM. Added value of diffusion-weighted MRI in detection of cervical cancer recurrence: comparison with morphologic and dynamic contrast-enhanced MRI sequences. Diagn Interv Radiol. 2015 Sep-Oct; 21(5): 368-75. doi: 10.5152/dir.2015.14427. PMID: 26200480; PMCID: PMC4557318. Go to original source... Go to PubMed...
  10. Höckel M. Laterally extended endopelvic resection (LEER)-principles and practice. Gynecol Oncol. 2008 Nov;111(2 Suppl):S13-7. doi: 10.1016/j.ygyno.2008.07.022. Epub 2008; Aug 23: PMID: 18723213. Go to original source... Go to PubMed...
  11. Moreno-Palacios E, Diestro MD, De Santiago J, Hernández A, Zapardiel I. Pelvic Exenteration in Gynecologic Cancer: La Paz University Hospital Experience. Int J Gynecol Cancer 2015 Jul; 25(6): 1109-14. doi: 10.1097/IGC.0000000000000435. PMID: 25853383. Go to original source... Go to PubMed...




Oncology

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.